Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity, may significantly reduce the risk of dementia, particularly in individuals with type 2 diabetes. Analysis of multiple trials indicates a 45% lower dementia risk associated with these drugs. Researchers emphasize the need for further studies to assess the benefits in non-diabetic populations. Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity, may significantly reduce the risk of dementia, particularly in individuals with type 2 diabetes. Analysis of multiple trials indicates a 45% lower dementia risk associated with these drugs. Researchers emphasize the need for further studies to assess the benefits in non-diabetic populations. Health and Fitness, Health Tips, Exercises & Workout Tips, Diet & Wellness | Times of India Lifestyle
